首页> 外国专利> Combined therapy with rammiditan and CGRP antagonist for use in migraine treatment

Combined therapy with rammiditan and CGRP antagonist for use in migraine treatment

机译:与哺乳动物和CGRP拮抗剂用于偏头痛治疗的组合治疗

摘要

The present invention is for the treatment of rasmiditane and calcitonin gene-related peptide (CGRP) antagonists, such as the combination of rasmiditane and galactanezumab, as well as migraine, especially migraine inappropriately controlled by lasmiditane or CGRP antagonist therapy alone. For more information on how to use that combination, the therapy resistance defined herein as migraine that is refractory to two or more conventional monotherapy and / or dual therapy treatment regimens. Regarding treating migraine.
机译:本发明用于治疗RasmIdantane和Calcitonin相关的肽(CGRP)拮抗剂,例如Rasmiditane和Galacteranezumab的组合,以及偏头痛,特别是由Lasmidine或CGRP拮抗剂治疗的偏头痛。 有关如何使用该组合的更多信息,本文定义的治疗抗性作为偏头痛,这对于两种或多种常规单药治疗和/或双治疗治疗方案难以难以。 关于治疗偏头痛。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号